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     Rationale:  Although the incidence of cannabis abuse/dependence in Americans is rising, the 
neurobiology of cannabis addiction is not well understood.  Previous PET and SPECT studies 
have demonstrated deficits in striatal D2/D3 receptor availability in several substance-
dependent populations.  However, this has not been studied in chronic cannabis users.   
     Objective: The purpose of this study was to compare striatal D2/D3 receptor availability 
between currently-using chronic cannabis users and healthy controls.   
     Methods: Eighteen right-handed males, 18-34 years of age, were studied.  Ten subjects were 
chronic cannabis users; eight were demographically matched controls. Subjects underwent a 
[11C]raclopride (RAC) PET scan.  On the scan day, urine samples were obtained from cannabis 
users for quantification of urine ∆-9-tetrahydrocannabinol (THC; the active compound in 
cannabis smoke) and THC metabolites (11-nor-∆-9-THC-9-carboxylic acid and 11-hydroxy-THC).  
Striatal RAC binding potential (BPND) was used as an index of D2/D3 receptor availability; this 
parameter was estimated at each image voxel for every subject.  SPM5 software was used to 
test for differences in BPND between groups and, in cannabis subjects, for associations between 
BPND and markers of cannabis use.   
     Results: There were no differences in D2/D3 receptor availability between     cannabis users 
and controls.  Smokers of either cannabis and/or tobacco had 10.2% lower BPND values than 
nonsmokers  in the bilateral putamen (“any-smokers”: 2.66 ± 0.2; nonsmokers: 2.97 ± 0.2).  In 
cannabis users, RAC BPND values were negatively associated with both urine levels of cannabis 
metabolites and self-report of recent cannabis consumption.   
     Conclusions:  There is an inverse relationship between chronic cannabis use and striatal RAC 
BPND. This may be caused by inhibition of monoamine oxidase (MAO) by the pyrolyzation of 
cannabis, which could lead to increased endogenous dopamine levels (and hence, lower BPND in 
heavier users).  Additional studies are needed to identify the neurochemical consequences of 
chronic cannabis use on the dopamine system. 
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